- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Institutional Culture and Sensitive Investigations
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
David J. Farber
Insights 36 results
Article · Source: Law360
September 17, 2024
CMS' New 'Breakthrough' Device Policy Shows Little Promise
Client Alert
September 4, 2024
Transitional Coverage for Emerging Technologies: CMS’s Latest, But Not Necessarily Greatest, Coverage with Evidence Approach
Client Alert
Client Alert
October 3, 2023
FDA's Latest Salvo in the LDT Wars
Client Alert
July 12, 2023
A Pathway for Medicare Coverage for Breakthrough Devices: Take Two
Article · Source: Alliance for Aging Research
February 13, 2023
Facade of Evidence: How Medicare's Coverage with Evidence Development Paradigm Rations Care and Exacerbates Inequity
Client Alert
August 15, 2022
Price Negotiation, Medicare Rebates, and Benefit Reform
Article · Source: Law360
June 29, 2022
High Court's Medicaid Ruling Brings Questions, Not Answers
COVID-19 Vaccine Updates
April 30, 2021
CDC Reveals New Guidelines for Fully Vaccinated Individuals
COVID-19 Vaccine Updates
April 30, 2021
CDC Says Pfizer and Moderna COVID-19 Vaccines are 94% Effective Against Hospitalization in Older Adults
COVID-19 Vaccine Updates
April 16, 2021
CDC and FDA Release Joint Statement on Johnson & Johnson COVID-19 Vaccine
COVID-19 Vaccine Updates
April 16, 2021
HHS Office for Civil Rights Publishes Legal Guidance Around Access to COVID-19 Vaccines for People with Disabilities and Older Adults